Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517556
Status:
COMPLETED
Last Update Posted:
2017-04-28
First Post:
2007-05-18
Brief Title:
Continuous Administration of Oral Contraceptive Primary Dysmenorrhea
Sponsor:
Milton S Hershey Medical Center
Organization:
Milton S Hershey Medical Center
Study Overview
Official Title:
Continuous Administration of a Monophasic Oral Contraceptive in the Treatment of Primary Dysmenorrhea
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Dysmenorrhea
Brief Summary:
The primary hypothesis is that continuous administration of an OCP CCOCP regimen will result in more pain relief than a traditional 217 administration in primary dysmenorrhea PD patients
Detailed Description:
It is well established that excess prostaglandin production in primary dysmenorrhea PD leads to ischemia of the uterine muscle which consequently causes pelvic pain A large number of drugs have been studied for pain relief in dysmenorrhea patients with non-steroid anti-inflammatory drugs NSAIDs being the most effective with the overall success rate of more than 75 Oral contraceptive pills OCP are also an established treatment for PD with the success rate of 70 Lately OCPs have been used continuously in patients with endometriosis and had better pain control than traditional administration of OCP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None